Vaxcyte Announces Pricing of $550 Million Public Offering

Core Viewpoint - Vaxcyte, Inc. has announced a public offering of common stock, aiming to raise $550 million through the sale of 11 million shares at a price of $50.00 per share, with an option for underwriters to purchase an additional 1.65 million shares [1][2]. Group 1: Offering Details - The public offering is expected to close on February 2, 2026, pending customary closing conditions [2]. - The offering is managed by several financial institutions, including BofA Securities, Jefferies, and Guggenheim Securities, among others [2]. Group 2: Company Overview - Vaxcyte is focused on developing high-fidelity vaccines to combat bacterial diseases, with notable candidates including VAX-31 and VAX-24, which are designed to prevent invasive pneumococcal disease [5][6]. - The company utilizes a proprietary cell-free protein synthesis platform, XpressCF®, to enhance the development of complex vaccines [6]. Group 3: Pipeline and Innovation - Vaxcyte's pipeline includes VAX-A1, aimed at preventing Group A Strep infections, and VAX-GI, designed to prevent Shigella [6]. - The company is innovating vaccine production methods to improve immunological benefits and expand coverage against various serotypes [5][6].